Gadelha M, Gatto F, Wildemberg LE, Fleseriu M. Cushing’s syndrome. Lancet. 2023;402:2237–52. https://doi.org/10.1016/S0140-6736(23)01961-X.

Article  PubMed  Google Scholar 

Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, et al. Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol. 2021;9:847–75. https://doi.org/10.1016/S2213-8587(21)00235-7.

Article  PubMed  PubMed Central  Google Scholar 

Giuffrida G, Crisafulli S, Ferrau F, Fontana A, Alessi Y, Calapai F, et al. Global Cushing’s disease epidemiology: a systematic review and meta-analysis of observational studies. J Endocrinol Invest. 2022;45:1235–46. https://doi.org/10.1007/s40618-022-01754-1.

Article  PubMed  CAS  Google Scholar 

Reincke M, Fleseriu M, Cushing Syndrome. Rev JAMA. 2023;330:170–81. https://doi.org/10.1001/jama.2023.11305.

Article  CAS  Google Scholar 

Nieman LK, Castinetti F, Newell-Price J, Valassi E, Drouin J, Takahashi Y, et al. Cushing syndrome. Nat Rev Dis Primers. 2025;11:4. https://doi.org/10.1038/s41572-024-00588-w.

Article  PubMed  Google Scholar 

Ding J, Tong A, Hacker M, Feng M, Huo L, Li X. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome. Clin Nucl Med. 2022;47:669–76. https://doi.org/10.1097/RLU.0000000000004244.

Article  PubMed  Google Scholar 

Wu Y, Wu Y, Yao B, Ren S, Wu S, Rui W, et al. Diagnostic Accuracy and Value of CXCR4-targeted PET/MRI Using (68)Ga-Pentixafor for Tumor Localization in Cushing Disease. Radiology. 2024;313:e233469. https://doi.org/10.1148/radiol.233469.

Article  PubMed  Google Scholar 

Horiguchi K, Ilmiawati C, Fujiwara K, Tsukada T, Kikuchi M, Yashiro T. Expression of chemokine CXCL12 and its receptor CXCR4 in folliculostellate (FS) cells of the rat anterior pituitary gland: the CXCL12/CXCR4 axis induces interconnection of FS cells. Endocrinology. 2012;153:1717–24. https://doi.org/10.1210/en.2011-1937.

Article  PubMed  CAS  Google Scholar 

Xing B, Kong YG, Yao Y, Lian W, Wang RZ, Ren ZY. Study on the expression levels of CXCR4, CXCL12, CD44, and CD147 and their potential correlation with invasive behaviors of pituitary adenomas. Biomed Environ Sci: BES. 2013;26:592–8. https://doi.org/10.3967/0895-3988.2013.07.011.

Article  PubMed  CAS  Google Scholar 

Barbieri F, Thellung S, Würth R, Gatto F, Corsaro A, Villa V, et al. Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. Int J Endocrinol. 2014;2014:753524. https://doi.org/10.1155/2014/753524.

Article  PubMed  PubMed Central  Google Scholar 

Bonneville JF, Potorac I, Petrossians P, Tshibanda L, Beckers A. Pituitary MRI in Cushing’s disease - an update. J Neuroendocrinol. 2022;34:e13123. https://doi.org/10.1111/jne.13123.

Article  PubMed  CAS  Google Scholar 

Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria.: R Foundation for Statistical Computing; 2024.

Google Scholar 

Ehman EC, Johnson GB, Villanueva-Meyer JE, Cha S, Leynes AP, Larson PEZ, et al. PET/MRI: Where might it replace PET/CT? J Magn Reson Imaging. 2017;46:1247–62. https://doi.org/10.1002/jmri.25711.

Article  PubMed  PubMed Central  Google Scholar 

Xiong W, Gao X, Zhang T, Jiang B, Hu MM, Bu X, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13:1700. https://doi.org/10.1038/s41467-022-29401-6.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tang J, Long G, Hu K, Xiao D, Liu S, Xiao L, et al. Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT. Adv Sci (Weinh). 2023;10:e2302953. https://doi.org/10.1002/advs.202302953.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Peng H, Yang F, Hu Q, Sun J, Peng C, Zhao Y, et al. The ubiquitin-specific protease USP8 directly deubiquitinates SQSTM1/p62 to suppress its autophagic activity. Autophagy. 2020;16:698–708. https://doi.org/10.1080/15548627.2019.1635381.

Article  PubMed  CAS  Google Scholar 

Florio T, Casagrande S, Diana F, Bajetto A, Porcile C, Zona G, et al. Chemokine stromal cell-derived factor 1alpha induces proliferation and growth hormone release in GH4C1 rat pituitary adenoma cell line through multiple intracellular signals. Mol Pharmacol. 2006;69:539–46. https://doi.org/10.1124/mol.105.015255.

Article  PubMed  CAS  Google Scholar 

Lee Y, Kim JM, Lee EJ. Functional expression of CXCR4 in somatotrophs: CXCL12 activates GH gene, GH production and secretion, and cellular proliferation. J Endocrinol. 2008;199:191–9. https://doi.org/10.1677/joe-08-0250.

Article  PubMed  CAS  Google Scholar 

Ma ZY, Song ZJ, Chen JH, Wang YF, Li SQ, Zhou LF, et al. Recurrent gain-of-function USP8 mutations in Cushing’s disease. Cell Res. 2015;25:306–17. https://doi.org/10.1038/cr.2015.20.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al. Mutations in the deubiquitinase gene USP8 cause Cushing’s disease. Nat Genet. 2015;47:31–8. https://doi.org/10.1038/ng.3166.

Article  PubMed  CAS  Google Scholar 

Perez-Rivas LG, von Selzam V, Sharma P, Reincke M, Theodoropoulou M. Prevalence and clinical associations of USP8 variants in corticotroph tumours: a systematic review and aggregate data meta-analysis of 2171 cases. Eur J Endocrinol. 2025;192:S41–52. https://doi.org/10.1093/ejendo/lvaf097.

Article  PubMed  CAS  Google Scholar 

Sbiera S, Kunz M, Weigand I, Deutschbein T, Dandekar T, Fassnacht M. The New Genetic Landscape of Cushing’s Disease: Deubiquitinases in the Spotlight. Cancers (Basel). 2019;11. https://doi.org/10.3390/cancers11111761.

Miao H, Liu Y, Lu L, Gong F, Wang L, Duan L, et al. Effect of 3 NR3C1 Mutations in the Pathogenesis of Pituitary ACTH Adenoma. Endocrinology. 2021;162. https://doi.org/10.1210/endocr/bqab167.

Perez-Rivas LG, Simon J, Albani A, Tang S, Roeber S, Assie G, et al. TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome. Acta Neuropathol Commun. 2022;10:139. https://doi.org/10.1186/s40478-022-01437-1.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in USP8 wild-type Cushing’s disease. Neuro Oncol. 2019;21:1273–83. https://doi.org/10.1093/neuonc/noz109.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Simon J, Theodoropoulou M. Genetics of Cushing’s disease. J Neuroendocrinol. 2022;34:e13148. https://doi.org/10.1111/jne.13148.

Article  PubMed  CAS  Google Scholar 

Zheng Y, Long T, Peng N, Zhen M, Ye Q, Zhang Z, et al. The Value of Targeting CXCR4 With 68Ga-Pentixafor PET/CT for Subtyping Primary Aldosteronism. J Clin Endocrinol Metab. 2023;109:171–82. https://doi.org/10.1210/clinem/dgad421.

Article  PubMed  CAS  Google Scholar 

Hu J, Xu T, Shen H, Song Y, Yang J, Zhang A, et al. Accuracy of Gallium-68 Pentixafor Positron Emission Tomography-Computed Tomography for Subtyping Diagnosis of Primary Aldosteronism. JAMA Netw open. 2023;6:e2255609. https://doi.org/10.1001/jamanetworkopen.2022.55609.

Article  PubMed  PubMed Central  Google Scholar 

Zheng WC, Chen SM, Qiu QR, Li XD, Lin F, Shen XM, et al. Total or partial adrenalectomy for aldosterone-producing adenoma: can (68)Ga-Pentixafor PET/CT predict surgical outcomes? Eur J Nucl Med Mol Imaging. 2025;52:3632–42. https://doi.org/10.1007/s00259-025-07244-9.

Article  PubMed  Google Scholar 

Ding J, Tong A, Zhang Y, Wen J, Zhang H, Hacker M, et al. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor. Journal of nuclear medicine: official publication. Soc Nuclear Med. 2022;63:368–75. https://doi.org/10.2967/jnumed.121.261964.

Article  CAS